

DAFTAR PUSTAKA

1. World Health Organization. Global action plan on the public health response to dementia 2017 - 2025. Geneva World Heal Organ. 2017;52.
2. Calderon-Garcidueñas AL, Duyckaerts C. Alzheimer disease. *Handb Clin Neurol*. 2018;
3. Bagyinszky E, Giau V Van, Shim K, Suk K, An SSA, Kim SY. Role of inflammatory molecules in the Alzheimer's disease progression and diagnosis. *J Neurol Sci*. 2017;376:242–54.
4. Ahmad MH, Fatima M, Mondal AC. Influence of microglia and astrocyte activation in the neuroinflammatory pathogenesis of Alzheimer's disease: Rational insights for the therapeutic approaches. *J Clin Neurosci*.
5. Kummer MP, Heneka MT. PPARs in Alzheimer's disease. *PPAR Res*. 2008;2008.
6. Prashantha Kumar BR, Kumar AP, Jose JA, Prabitha P, Yuvaraj S, Chipurupalli S, et al. Minutes of PPAR- γ agonism and neuroprotection. *Neurochem Int*. 2020;140(July):104814.
7. Hayashi Y, Lin HT, Lee CC, Tsai KJ. Effects of neural stem cell transplantation in Alzheimer's disease models. *J Biomed Sci*. 2020;27(1):1–11.
8. Guo M, Yin Z, Chen F, Lei P. Mesenchymal stem cell-derived exosome: A promising alternative in the therapy of Alzheimer's disease. *Alzheimer's Res Ther*. 2020;12(1):1–14.
9. Fuchs E, Chen T. A matter of life and death: Self-renewal in stem cells. *EMBO Rep*. 2013;14(1):39–48.
10. Wang X. Stem cells in tissues, organoids, and cancers. *Cell Mol Life Sci*. 2019;76(20):4043–70.
11. Lee JH, Oh IH, Lim HK. Stem cell therapy: A prospective treatment for Alzheimer's disease. *Psychiatry Investig*. 2016;13(6):583–9.
12. Elia CA, Losurdo M, Malosio ML, Coco S. Extracellular Vesicles from Mesenchymal Stem Cells Exert Pleiotropic Effects on Amyloid- β , Inflammation, and Regeneration: A Spark of Hope for Alzheimer's Disease from Tiny Structures? *BioEssays*. 2019;41(4):1–10.
13. Wang SM, Lee CU, Lim HK. Stem cell therapies for Alzheimer's disease: Is it time? *Curr Opin Psychiatry*. 2019;32(2):105–16.
14. Schnegg CI, Robbins MF. Neuroprotective mechanisms of PPAR δ : Modulation of oxidative stress and inflammatory processes. *PPAR Res*. 2011;2011.

15. Guo T, Zhang D, Zeng Y, Huang TY, Xu H, Zhao Y. Molecular and cellular mechanisms underlying the pathogenesis of Alzheimer's disease *Mol Neurodegener.* 2020;15(1):1–37.
16. Cass SP. Alzheimer's disease and exercise: A literature review. *Curr Sports Med Rep.* 2017;16(1):19–22.
17. Bird TD. Alzheimer Disease Overview 1 . Clinical Characteristics of Alzheimer Disease. *Gene Rev.* 2018;1–12.
18. Henly H. Alzheimer ' s Disease : Epidemiology , Risks , and Testing. *Rga.* 2020;(June).
19. Demensia D, Medan DI, Utara S. Darmabakti Cendekia : Caregiver Training on Care for People With. 2020;02:1–3.
20. Sheppard O, Coleman M. Alzheimer's Disease: Etiology, Neuropathology and Pathogenesis. *Alzheimer's Dis Drug Discov.* 2020;1–22.
21. Kumar A, Sidhu J, Goyal A, Tsao JW. Alzheimer Disease. StatPearls Publishing, Treasure Island (FL); 2021.
22. Calabrò M, Rinaldi C, Santoro G, Crisafulli C. The biological pathways of Alzheimer disease: A review. *AIMS neuroscience.* ncbi.nlm.nih.gov; 2021.
23. 2019 Alzheimer's disease facts and figures *Alzheimer's Dement.* 2019;15(3):321–87.
24. Ary K, Pattni M, Udayana U. Beta-Amyloid As Pathogenesis of Alzheimer Disease. *e-Jurnal Med Udayana.* 2013;2(8):1306–17.
25. Eratne D, Loi SM, Farrand S, Kelso W, Velakoulis D, Looi JCL. Alzheimer's disease: clinical update on epidemiology, pathophysiology and diagnosis. *Australas Psychiatry.* 2018;26(4):347–57.
26. Folch J, Busquets O, Etcheto M, Sánchez-López E, Castro-Torres RD, Verdagué E, et al. Memantine for the treatment of dementia: A review on its current and future applications *J Alzheimer's Dis.* 2018;62(3):1223–40.
27. Morsy A, Trippier PC. Amyloid-Binding Alcohol Dehydrogenase (ABAD) Inhibitors for the Treatment of Alzheimer's Disease. *J Med Chem.* 2019;62(9):4252–64.
28. Srivastava S, Ahmad R, Khare SK. Alzheimer's disease and its treatment by different approaches: A review. *Eur J Med Chem.* 2021;216:113320.
29. Yiannopoulou KG, Papageorgiou SG. Current and Future Treatments in Alzheimer Disease: An Update. *J Cent Nerv Syst Dis.* 2020;12:117957352090739.
30. Cai W, Yang T, Liu H, Han L, Zhang K, Hu X, et al. Peroxisome proliferator-activated receptor γ (PPAR γ): A master gatekeeper in CNS injury and repair.

Prog Neurobiol. 2018;163–164:27–58.

31. Wu L, Guo C, Wu J. Therapeutic potential of PPAR γ natural agonists in liver diseases. *J Cell Mol Med*. 2020;24(5):2736–48.
32. Laferla FM. clinical implications of basic research Preclinical Success against Alzheimer ' s Disease with an Old Drug. *N Engl J Med*. 2012;367(6):570–2.
33. Zhang M, Qian C, Zheng ZG, Qian F, Wang Y, Thu PM, et al. Jujuboside A promotes A β clearance and ameliorates cognitive deficiency in Alzheimer's disease through activating Axl/HSP90/PPAR γ pathway. *Theranostics*. 2018;8(15):4262–78.
34. Vallée A, Lecarpentier Y, Guillevin R, Vallée JN. Effects of cannabidiol interactions with Wnt/ β -catenin pathway and PPAR γ on oxidative stress and neuroinflammation in Alzheimer's disease. *Acta Biochim Biophys Sin (Shanghai)*. 2017;49(10):853–66.
35. Sarkar A, Saha S, Paul A, Maji A, Roy P, Maity TK. Understanding stem cells and its pivotal role in regenerative medicine. *Life Sci*. 2021;273(February):119270.
36. Chakari-Khiavi F, Dolati S, Chakari-Khiavi A, Abbaszadeh H, Aghcbati-Maleki L, Poulak T, et al. Prospects for the application of mesenchymal stem cells in Alzheimer's disease treatment. *Life Sci*. 2019;231(June).
37. Zhang L, Dong Z fang, Zhang J yuan. Immunomodulatory role of mesenchymal stem cells in Alzheimer's disease. *Life Sci*. 2020;246(December 2019):117405.
38. Saecdi P, Halabian R, Fooladi AAL. A revealing review of mesenchymal stem cells therapy, clinical perspectives and Modification strategies. *Stem Cell Investig*. 2019;6.
39. Bodart-santos V, Carvalho LRP De, Godoy MA De, Batista AF, Saraiva LM, Lima LG, et al. Extracellular vesicles derived from human Wharton ' s jelly mesenchymal stem cells protect hippocampal neurons from oxidative stress and synapse damage induced by amyloid- β oligomers. 2019;5:1–13.
40. Zhao Y, Chen X, Wu Y, Wang Y, Li Y, Xiang C. Transplantation of human menstrual blood-derived mesenchymal stem cells alleviates alzheimer's disease-like pathology in app/ps1 transgenic mice. *Front Mol Neurosci*. 2018;11(April):1–14.
41. Liao LL, Ruszymah BHI, Ng MH, Law JX. Characteristics and clinical applications of Wharton's jelly-derived mesenchymal stromal cells. *Curr Res Transl Med*. 2020;68(1):5–16.
42. Wang Q, Yang Q, Wang Z, Tong H, Ma L, Zhang Y, et al. Comparative analysis of human mesenchymal stem cells from fetal-bone marrow, adipose

tissue, and Wharton's jelly as sources of cell immunomodulatory therapy. *Hum Vaccines Immunother.* 2016;12(1):85–96.

43. Eqbal Z, Baligar PN, Srivastava M, Mukhopadhyay A. A Two-Stage Process for Differentiation of Wharton's Jelly-Derived Mesenchymal Stem Cells into Neuronal-like Cells. *Stem Cells Int.* 2021;2021.
44. Amable PR, Teixeira MVT, Carias RBV, Granjeiro JM, Borojevic R. Gene expression and protein secretion during human mesenchymal cell differentiation into adipogenic cells. *BMC Cell Biol.* 2014;15(1):1–10.
45. Zhang L, Chen C, Mak MSH, Lu J, Wu Z, Chen Q, et al. Advance of sporadic Alzheimer's disease animal models. *Med Res Rev.* 2020;40(1):431–58.
46. Benedikz E, Kloskowska E, Winblad B. The rat as an animal model of Alzheimer's disease. *J Cell Mol Med.* 2009;13(6):1034–42.
47. Shunan D, Yu M, Guan H, Zhou Y. Neuroprotective effect of Betalain against A β 13-induced Alzheimer's disease in Sprague Dawley Rats via putative modulation of oxidative stress and nuclear factor kappa B (NF- κ B) signaling pathway. *Biomed Pharmacother.* 2021;137(November 2020):111369.
48. İpek Konaklı M. Alzheimer's Disease and Animal Models. *J Exp Basic Med Sci.* 2021;1(3):107–12.
49. Kim H, Na DL, Lee NK, Kim AR, Lee S, Jang H. Intrathecal injection in a rat model: A potential route to deliver human wharton's jelly-derived mesenchymal stem cells into the brain. *Int J Mol Sci.* 2020;21(4):1–12.
50. WHO. General Guidelines for Methodologies on Research and Evaluation of Traditional Medicine World Health Organization. 2000;1–73.
51. Imperatore JA, Then ML, McDougal KB, Mihailescu MR. Characterization of a G-Quadruplex structure in pre-miRNA-1229 and in its alzheimer's disease-associated variant rs2291418: Implications for miRNA-1229 maturation. *Int J Mol Sci.* 2020;21(3).
52. Aboelwafa HR, El-Kott AF, Abd-Ella EM, Yousef HN. The possible neuroprotective effect of silymarin against aluminum chloride-prompted alzheimer's-like disease in rats. *Brain Sci.* 2020;10(9):1–21.
53. Yarni DS. Pengaruh Pemberian Mesenchymal Stem Cell Wharton Jelly Terhadap Ekspresi Gen *Calm1* dan *Casp9* Tikus Alzheimer. 2021.
54. Indrianti M. Deteksi Kandungan Babi Pada Produk Olahan Daging Menggunakan Metode Multiplex Pcr Di Kabupaten Pandeglang. *Biodidaktika J Biol Dan Pembelajarannya.* 2021;16(1).
55. Shunan D, Yu M, Guan H, Zhou Y. Neuroprotective effect of Betalain against A β 13-induced Alzheimer's disease in Sprague Dawley Rats via putative modulation of oxidative stress and nuclear factor kappa B (NF- κ B)

- signaling pathway. *Biomed Pharmacother.* 2021 May 1;137:111369.
56. Promyo K, Iqbal F, Chaidee N, Chetsawang B. Aluminum chloride-induced amyloid β accumulation and endoplasmic reticulum stress in rat brain are averted by melatonin. 2020;146(August).
 57. Quan Q, Wang J, Li X, Wang Y. Ginsenoside Rg1 Decreases A β 1 – 42 Level by Upregulating PPAR γ and IDE Expression in the Hippocampus of a Rat Model of Alzheimer ' s Disease. 2013;8(3):2–9.
 58. Govindarajulu M, Pinky PD, Bloemer J, Suppiramaniam V, Amin R, Ghanei N. Signaling Mechanisms of Selective PPAR γ Modulators in Alzheimer ' s Disease. 2018;2018.
 59. Satvik K, Swapna B, M KV, Setty SR, Kumar BH, Harisha R. ce pt us cr. *J Biomol Struct Dyn.* 2020;0(03):000.
 60. Mohamed EA, Ahmed HI, Zaky HS, Badr AM. Jo ur na l P re of. *Journal of Ethnopharmacology.* Elsevier B.V.; 2020. 113468 p.
 61. Blume T, Deussing M, Biechele G, Peters F, Zott B, Schmidt C, et al. Chronic PPAR γ Stimulation Shifts Amyloidosis to Higher Fibrillarity but Improves Cognition. *Front Aging Neurosci.* 2022;14(March):1–13.
 62. Marinelli R, Torquato P, Bartolini D, Mas-Bargues C, Bellezza G, Gioiello A, et al. Garcinoic acid prevents β -amyloid (A β) deposition in the mouse brain. *J Biol Chem.* 2020;295(33):11866–76.
 63. Crane AT, Voth JP, Shen FX, Low WC. Concise Review: Human-Animal Neurological Chimeras: Humanized Animals or Human Cells in an Animal? *Stem Cells.* 2019;37(4):444–52.
 64. Qin C, Li Y, Wang K. Functional mechanism of bone marrow-derived mesenchymal stem cells in the treatment of animal models with alzheimer's disease: Inhibition of neuroinflammation. *J Inflamm Res.* 2021;14(August):4761–75.
 65. Babcock KR, Page JS, Fallon JR, Webb AE. Adult Hippocampal Neurogenesis in Aging and Alzheimer's Disease. *Stem Cell Reports.* 2021;16(4):681–93.
 66. Zhang X, Liu L, Dou C, Cheng P, Liu L, Liu H, et al. PPAR Gamma-Regulated MicroRNA 199a-5p Underlies Bone Marrow Adiposity in Aplastic Anemia. *Mol Ther - Nucleic Acids.* 2019;17(September):678–87.
 67. Zhang X, Lei T, Wang D, Cai S, Hang Z, Yang Y, et al. Stem cells from human exfoliated deciduous teeth relieves Alzheimer's disease symptoms in SAMP8 mice by up-regulating the PPAR γ pathway. *Biomed Pharmacother.* 2022;152(April):113169.
 68. Costa LA, Eiro N, Fraile M, Gonzalez LO, Saá J, Garcia P, et al. Functional heterogeneity of mesenchymal stem cells from natural niches to culture

conditions: implications for further clinical uses. *Cell Mol Life Sci.* 2020;(0123456789).

69. Reza-Zaldivar EE, Hernández-Sapiéns MA, Gutiérrez-Mercado YK, Sandoval-Ávila S, Gomez-Pinedo U, Márquez-Aguirre AL, et al. Mesenchymal stem cell-derived exosomes promote neurogenesis and cognitive function recovery in a mouse model of Alzheimer's disease. *Neural Regen Res.* 2019;14(9):1626–34.
70. Yang H, Xie Z, Wei L, Yang H, Yang S, Zhu Z, et al. Human umbilical cord mesenchymal stem cell-derived neuron-like cells rescue memory deficits and reduce amyloid-beta deposition in an A β PP / PS1 transgenic mouse model. 2013.
71. Kim K, Lee S, Kegelman TP, Su Z, Das SK, Dash R, et al. Role of Excitatory Amino Acid Glutamate in Neurodegeneration: Opportunities for Developing Novel Therapeutics. 2010;2(December):2484–93.

